The Management Team brings a rich heritage of experience and knowledge to Worldwide Clinical Trials.  The combined expertise of the Management Team is the foundation for our unparalled reputation of being therapeutic experts in CNS, Oncology, Cardiovascular, Chronic Inflammatory Disease and Respiratory drug development. Additionally, the Management Team works in a highly collaborative and consultatative manner, ensuring the development of trial methodologies that are highly tailored, innovative and designed to meet or exceed client needs.

Late Phase Drug Development

Worldwide Clinical Trials Late Phase expertise includes pre-registration  and post-approval   clinical drug development programs 

• Christopher L. Crucitti, MS
  Executive Vice President, Global Business Development
• Paola Antonini, M.D., Ph.D.
  Senior Vice President, Medical & Scientific Affairs, Drug Safety
• Henry J. Riordan, Ph.D.
  Senior Vice President, Medical and Scientific Affairs

• Doniel L. Jackson, M.D.
  Vice President, Medical and Scientific Affairs, Global Medical Monitoring and Drug Safety
• Graham Downing
  Vice President, Global Data, Statistics and Technology
• Jeffrey Weisberg, D.O., FACP
  Vice President, Medical and Scientific Affairs, Oncology

Early Phase Services and Bioanalytical Sciences

WCT Early Phase Services and Bioanalytical Sciences are divisions of Worldwide Clinical Trials with expertise in early phase drug development; small and large molecule bioanalysis 

• Anthony G. Busa Jr. 
  President/CEO
• Sherilyn Adcock, R.Ph., Ph.D. 
  Senior Vice President, Chief Scientific Officer
• Steve Peck
  Senior Director, Clinical Research Services

• Steve E. Unger, Ph.D. 
  Senior Vice President/Laboratory Director, Bioanalytical Sciences
• William Nowatzke, Ph.D.  
  Director Ligand Binding Assay Laboratory, Bioanalytical Sciences
• Michele Malone, B.S. 
  Director Laboratory Operations, Bioanalytical Sciences